My Watchlist
Indicators
REW 40 Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Viridian Therapeutics, Inc. - Common Stock (NQ:VRDN)

23.78 +0.77 (+3.35%)
Streaming Delayed Price Updated: 11:51 AM EDT, Oct 17, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Viridian Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 Next >
Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Viridian Therapeutics, Inc.
Via Business Wire
This Sarepta Therapeutics Analyst Begins Coverage On A Bearish Note; Here Are Top 5 Initiations For Monday
 
Via Benzinga
In-Depth Examination Of 11 Analyst Recommendations For Viridian Therapeutics
 
Via Benzinga
Viridian Therapeutics Reports Third Quarter 2024 Financial Results and Recent Progress Including New FcRn Data
From Viridian Therapeutics, Inc.
Via Business Wire
Analyst Expectations For Viridian Therapeutics's Future
 
Via Benzinga
Forecasting The Future: 13 Analyst Projections For Viridian Therapeutics
 
Via Benzinga
Critical Insights From Viridian Therapeutics Analyst Ratings: What You Need To Know
 
Via Benzinga
Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Viridian Therapeutics, Inc.
Via Business Wire
Viridian Therapeutics Announces Pricing of Upsized Public Offering of Shares of Common Stock and Preferred Stock
From Viridian Therapeutics, Inc.
Via Business Wire
Viridian Therapeutics Announces Proposed Underwritten Public Offering of Common Stock and Preferred Stock
From Viridian Therapeutics, Inc.
Via Business Wire
Decoding 6 Analyst Evaluations For Viridian Therapeutics
 
Via Benzinga
Expert Ratings For Viridian Therapeutics
 
Via Benzinga
Calavo Growers Posts Better-Than-Expected Earnings, Joins Tesla, Oracle, Mission Produce And Other Big Stocks Moving Higher On Tuesday
 
Via Benzinga
Viridian Spikes On A 'Bull-Case Scenario' For Eye Drug Considered Amgen Rival
The results are also promising for the next-generation version of that drug. 
Via Investor's Business Daily
Viridian Therapeutics Discloses 'Exciting' Data From Experimental Thyroid Eye Disease Candidate, Says Data Met High Bars For Efficacy, Safety
Viridian Therapeutics announced promising topline data from the THRIVE phase 3 trial of VRDN-001 (veligrotug) for active thyroid eye disease meeting all primary and secondary endpoints. Viridian plans... 
Via Benzinga
Viridian Therapeutics Announces Positive Topline Results from Veligrotug (VRDN-001) Phase 3 THRIVE Clinical Trial in Patients with Active Thyroid Eye Disease
From Viridian Therapeutics, Inc.
Via Business Wire
Why Oracle Shares Are Trading Higher By Around 9%; Here Are 20 Stocks Moving Premarket
 
Via Benzinga
Viridian Therapeutics to Webcast VRDN-001 Phase 3 THRIVE Topline Results on September 10, 2024
From Viridian Therapeutics, Inc.
Via Business Wire
Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Viridian Therapeutics, Inc.
Via Business Wire
VRDN Stock Earnings: Viridian Therapeutics Misses EPS, Misses Revenue for Q2 2024
VRDN stock results show that Viridian Therapeutics missed analyst estimates for earnings per share and missed on revenue for the second quarter of 2024. 
Via InvestorPlace
Viridian Therapeutics Highlights Recent Progress and Reports Second Quarter 2024 Financial Results
From Viridian Therapeutics, Inc.
Via Business Wire
Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Viridian Therapeutics, Inc.
Via Business Wire
Top 3 Health Care Stocks You May Want To Dump This Quarter
 
Via Benzinga
Viridian Therapeutics Announces Completion of THRIVE-2 Enrollment for VRDN-001 in Patients with Chronic Thyroid Eye Disease (TED)
From Viridian Therapeutics, Inc.
Via Business Wire
Biogen Has Up To $10 Billion For Acquisitions; Why These Three Names Make Sense
Biogen has $8 billion to $10 billion in dry powder for acquisitions. Here are three names the company could examine. 
Via Investor's Business Daily
3 Small-Cap Stocks With Explosive 2X Growth Potential
Discover three top high-growth small-cap stocks, fueled by potential rate cuts and promising prospects in the second half of 2024. 
Via InvestorPlace
Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Viridian Therapeutics, Inc.
Via Business Wire
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
 
Via Benzinga
Viridian Therapeutics Announces Details of Subcutaneous VRDN-003 Phase 3 Clinical Program for Patients with Active and Chronic Moderate-to-Severe Thyroid Eye Disease
From Viridian Therapeutics, Inc.
Via Business Wire
Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Viridian Therapeutics, Inc.
Via Business Wire
< Previous 1 2 3 4 5 6 7 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.